Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.62
- Piotroski Score 2.00
- Grade Overweight
- Symbol (MRNA)
- Company Moderna, Inc.
- Price $41.15
- Changes Percentage (7.58%)
- Change $2.9
- Day Low $37.76
- Day High $42.40
- Year High $170.47
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $145.00
- High Stock Price Target $304.00
- Low Stock Price Target $55.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$15.59
- Trailing P/E Ratio -9.69
- Forward P/E Ratio -9.69
- P/E Growth -9.69
- Net Income $-4,714,000,000
Income Statement
Quarterly
Annual
Latest News of MRNA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
mRNA Shot Directly Linked To Transverse Myelitis
The article discusses the link between mRNA vaccines and transverse myelitis, highlighting the potential risks associated with these shots. It emphasizes the importance of addressing inflammation trig...
By The Washington Standard | 4 days ago -
BioNTech SE's Strategic Growth in Oncology and mRNA
BioNTech SE is expanding its oncology portfolio and advancing mRNA cancer vaccines, with a strong financial standing of €17.8 billion in cash and investments. The company's innovative technologies a...
By Yahoo! Finance | 1 week ago -
Inflammatix begins trial evaluating mRNA test for patient infection status
Inflammatix is conducting the TIMED trial to evaluate its TriVerity test for rapid diagnosis of infection and sepsis, aiding in antimicrobial therapy decisions. The trial aims to improve patient care ...
By Yahoo! Finance | 1 week ago
